The influence of coagulation cascade targets in CVD

Cardiovascular disease (CVD) is a general term for a variety of different diseases and conditions affecting the heart or blood vessels.

Share

Cardiovascular disease (CVD) is a general term for a variety of different diseases and conditions affecting the heart or blood vessels.

Stroke is expected to remain a major burden across the US and EU, even though the mortality attributable to stroke continues to decline.

The marketed pharmacotherapeutic treatments for diseases affecting people with CVD focuses on controlling the risk factors and complications in stroke.

Coagulation cascade targets have become increasingly prevalent in CVD therapies recently.

This partially reflects the stroke pipeline for CVD, which shows an increasing commercial presence of these targets, as illustrated in the chart below.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of target, coagulation cascades account for 58% of the pipeline, due to the diverse functions that they mediate.

As it is still an emerging class of therapy, this can be expected, but it may take more time for its pipeline size to translate into commercial dominance.

However, despite the large pipeline size, there are opportunities for growth within this group.

Related reports:

Global Cardiovascular Disease Drugs Market to 2023 – Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

More Relevant

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close